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Public health genomics raises exciting possibilities for preventing or reducing the 
occurrence of both rare and common disease. However, this area of research raises 
challenging ethical, legal and social issues that should be addressed. One way of 
addressing these issues is through public involvement in the policy-making process. This 
GenEdit reviews how international guidelines and policy statements related to public 
health genomics address the issue of public involvement. Key areas of discussion are the 
values and goals justifying public involvement, the proposed activities to increase public 
involvement, who is and who represents ‘the public’, as well as the projected outcomes of 
such involvement.  
 
 
An important goal of genomics in public 
health is to prevent or reduce the 
occurrence of both rare and common 
diseases. For example, newborn screening 
for phenylketonuria is a model for the 
prevention of treatable, rare genetic 
disorders. The demonstrable benefit of this 
programme is often mentioned in the hope 
that similar benefits may result from the use 
of population screening strategies. Similarly, 
in the era of genome-wide association 
studies, it is hoped that studying the 
interplay of genes with environmental and 
lifestyle factors for common diseases such 
as diabetes, heart disease, and cancer can 
help drive preventative strategies and 
reduce the risk of these common diseases.  
Despite the optimism associated with 
newborn screening programs, genome wide 
association studies and the use of biobanks, 
the intermingling of genomics with public 
health raises social, ethical and legal 
challenges that have the potential to affect 
the lives of many citizens. An example is 
Tandem Mass Spectrometry (TMS), which 
allows simultaneous screening of a number 
of conditions during the newborn period.1 In 
addition, for many conditions detected by 
TMS, no direct medical benefit is available, 
thus raising ethical, legal and social 
concerns about expanding the use of 
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newborn screening. Moreover, samples 
collected for newborn screening could 
identify carrier status and genetic 
susceptibility to adult onset diseases (e.g. 
BRCA1/2 for breast cancer or ApoE for 
Alzheimer’s Disease) which, if disclosed to 
parents, may violate the child’s privacy 
rights.2 Likewise, public health research 
using whole-genome genotyping or in the 
foreseeable future, whole genome 
sequencing technology for genetic 
susceptibility testing, raises several 
concerns,3 including: what to tell those who 
participate, whether to inform the extended 
family, and how  samples or data will be 
used in the future.4    
 
The identification of genetic determinants 
using genome-wide association studies 
requires large biobanks and their use raises 
additional ethical concerns regarding data 
privacy and security,5 issues of 
discrimination, stigmatization and social 
harm, as well as concerns about reinforcing 
genetic exceptionalism or determinism.6 In 
short, as we entertain the potential for 
genomics to promote public health, 
questions arise about the appropriateness 
of, for example, expanded newborn 
screening programs, the use of genetic 
susceptibility testing for common diseases, 
and the use of biobanks.  
 
One safeguard to address these social, 
ethical and legal issues is public 
involvement. Involving the public in a debate 
on emerging scientific developments, such 
as genomics and public health, is 
recognized as a timely and fruitful approach 
to policy making.7 Seeking public 
involvement in policy development and 
decision-making has been recognized as an 
activity that will help shape the health 
system,8 build greater trust in science,9 
strengthen democratic ideals and enhance 
trust in governments,10 improve the 
relevance and translation of research into 
practice,11 empower citizens,12 improve 
governance,13 and provide access to 
unexploited knowledge.14 
 
Greater public involvement in policy 
development has been propelled by a range 
of factors including public demand for 
accountability,15 and as a means to counter 
public anxieties associated with advances in 
genomics, as was the case with (GM) 
food.16 Moreover, linking genetics to public 
health rests on the principles of justice, 
public goods,17 solidarity,18 public trust,19 
and respect for cultural, religious, legal, and 
social diversity. 
 
This paper reviews how international 
guidelines and policy statements related to 
public health genomics address the issue of 
public involvement. We start with a brief 
overview of various organizations that have 
a mandate to work toward public 
involvement in general. Then, we review 
international policy statements that focus on 
public health genomics for insight into 
whether public involvement finds a voice in 
this sphere. We then focus our discussion 
on four questions that have been identified 
through an analysis of the literature on 
public participation: a) what are the values 
and guiding principles that justify public 
involvement? b) what are the proposed 
activities? c) who is, and who represents the 
public? and, d) what are the projected 
outcomes and how will these be evaluated?  
 
Bringing the Public into Public Health 
Genomics 
 
‘Public involvement’ in this article is used to 
denote interactions between the public and 
policy development agencies, and ranges 
from activities focusing on informing the 
public to activities that engage the public in 
research and policy-making.  
 
A number of international organizations 
have a mandate to promote public 
involvement and have issued 
recommendations to guide the process. For 
example, the International Association for 
Impact Assessment (IAIA) created principles 
for public participation and plays an 
important role in advancing innovation and 
communication of ‘best practices’ for 
professional’s, decision makers, and 
regulators.20 Another major organization 
promoting public involvement is the 
International Association for Public 
Participation (IAP2), whose role is to help 
organizations and communities around the 
world improve their decision-making abilities 
by involving the people affected by those 
decisions. Their guidelines invite interested 
publics into the decision-making process 
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and show that public participation can range 
from informing to consulting, and ultimately, 
to empowering the public.21  
 
Several other international organizations 
have developed recommendations 
promoting public involvement. The 
Convention on Access to Information, Public 
Participation in Decision-making and Access 
to Justice in Environmental Matters, by the 
United Nations Economic Commission for 
Europe (UNECE) stresses the legal 
obligation of governments to involve all 
stakeholders (including the public), when 
addressing environmental issues, in order to 
build public accountability and 
transparency.22  
 
Specific mandates concerning public 
involvement have been incorporated by the 
United Nations Educational, Scientific and 
Cultural Organization (UNESCO), which 
calls for public participation in their 
Constitution23 and in their Directives.24 The 
World Health Organization, which co-
ordinates and leads on international health 
issues, also plays an important role in this 
field.  The WHO Constitution, at Article 
18(h), states that the functions of the World 
Health Assembly shall be: 
 
to invite any organization, international or 
national, governmental or non-governmental, 
which has responsibilities related to those of 
the Organization, to appoint representatives 
to participate, without right of vote, in its 
meetings or in those of the committees and 
conferences convened under its authority, on 
conditions prescribed by the Health 
Assembly25 
 
At the regional level, the European 
Commission places emphasis on several 
approaches to public input, including 
parliamentary means, consultations with key 
organizations, and informal interactions with 
interested parties.26  The Organization for 
Economic Co-operation and Development 
(OECD) has made substantial commitment 
to engaging the public in the policy-making 
process and developed guidance 
documents for their member countries.27 
 
This brief overview broadly demonstrates 
the commitment of several international 
organizations to making the public an 
integral component of policy development 
and decision-making. This leads us to 
consider how “public involvement” is 
realized and defined in the policy statements 
addressing public health genomics. We 
searched for French and English documents 
published since 1995, by international and 
regional organizations, that included 
recommendations or statements about 
public involvement relevant to public health 
genetics using the following keywords: 
biobanks, newborn screening, genetic 
testing and pharmacogenomics. We 
categorize the results as follows. 
 
What values and goals justify public 
involvement? 
 
For purpose of this article, values are 
defined as beliefs, goals, or moral or ethical 
principles that contribute to 
recommendations. Most international and 
regional policy documents introduce the 
topic of public involvement by setting goals 
or guiding principles.  We identified three 
recurring themes: i) building trust and public 
confidence, ii) demonstrating transparency 
and openness, and iii) a range of other goals 
such as: formulating culturally appropriate 
policies; promoting solidarity and 
collaboration; and stimulating democratic 
renewal and equity. 
 
i) Trust and Public Confidence 
 
Several policies state that public 
involvement is important for fostering trust 
and public confidence. In a report on 
confidentiality and genetic data, the 
International Bioethics Committee of 
UNESCO states the importance of 
discussing questions about genetic data with 
the public “…so as to ward off both morbid 
distrust and blind confidence”.28 The WHO 
guideline on genetic databases encourages 
public debate prior to establishing databases 
“…to heighten awareness and foster trust in 
the endeavour…”.29 In the context of 
pharmacogenomic research, the Human 
Genome Organization (HUGO),  an 
international organization of scientists 
involved in genomic research, states that 
researchers have an obligation to engage 
the community so as “to earn the trust of the 
community”.30 HUGO’s reference to trust is 
not limited to pharmacogenomics. In the 
context of gene therapy research, it “urges 
researchers, professional organisations, 
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sponsors and governments to listen and 
respond to public concerns”.31 The 
European Commission, in their 
recommendations on the use of genetic 
tests, maintains that: 
 
The successful development and use of 
genetic tests is dependent on the interests 
and concerns of a wide range of stakeholders 
being recognized and responded to 
constructively. Failure to take this into 
account will result in a loss of confidence by 
certain stakeholders and could lead to an 
interruption in the developmental pathway 
that a diagnostic test follows from innovative 
scientific idea to clinical utility.32  
 
ii) Openness/Transparency 
 
Several policy statements call for openness 
and transparency.33 In this regard, as early 
as 1990, the Council for the International 
Organization of Medical Services (CIOMS), 
a non-governmental organization that plays 
an important role in the protection of human 
rights in biomedicine, stated that “…plans for 
the medical use of genetic findings and 
techniques will be made openly and 
responsibly”.34  The rationale behind this 
proposal is that public fears about genetics 
are in part based on misconceptions that 
open discussions should help redress. In 
addition, WHO guidelines on the operation 
of large genetic databases state that this  
“…should be carried out in an atmosphere of 
openness, transparency and appropriate 
ethical scrutiny.”35 In the same vein, the 
European Union, in their Resolution on 
future community action in the field of public 
health encourages“…that all health-related 
activities in the Community have a high-
degree of visibility and transparency, in 
order to promote better knowledge and thus 
enable a larger involvement of citizens”.36   
 
iii) Other goals 
 
The goals of public involvement are not 
restricted to building trust and transparency. 
Some policy statements recognize the need 
to introduce diverse public perspectives in 
order to foster “dialogue and cooperation 
[…] to establish and implement genetic 
services in a manner that is culturally 
acceptable and maximizes the health benefit 
to patients.”37 Others place the focus on 
health equity,38 or speak of democratization 
and the need to “…enable a larger 
involvement of citizens”,39 as well as give 
people a right to be involved in decisions 
that affect their lives.40 Based on the “right 
to equality”, Disabled People International 
demands to be included in debates involving 
bioethical issues.41 Furthermore, the 
International HapMap Consortium 
acknowledges that in socially and culturally 
sensitive environments, the contribution of 
the public is important and should be 
integrated into research by allowing the 
public the “…opportunity to share with 
investigators their views on the ethical, 
social and cultural issues…”.42 The 
International HUGO Statement on Human 
Genomic Databases states that “[p]ublic 
engagement is a prerequisite of public 
responsibility”.43 
 
What are the proposed activities to 
increase public involvement? 
 
It is important to note that terminology for 
public involvement activities is varied and 
includes terms such as information, 
education, communication, consultation, 
engagement, participation, dialogue, 
partnership, collaboration and input, which 
are often used interchangeably. While a 
comprehensive review of each term is 
beyond the scope of this paper, public 
involvement may be loosely grouped into 
two activities: i) education, and ii) direct or 
indirect input.44 
 
Public education is best characterized as 
providing information to the public, and is 
either seen as passive--if experts act on 
behalf of the public, or active--if there is an 
exchange of views (questions and answers). 
Public involvement--direct or indirect--is 
increasingly recognized as a more 
meaningful approach to public 
participation.45 An indirect approach 
suggests the one-way flow of information 
from the public toward policy-making bodies 
(eg consultation, survey), whereas direct 
input is described as a two-way exchange 
between the public and policy making 
bodies (eg deliberative democracy).46  
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i) Education 
 
Education as a public involvement strategy 
is supported by numerous organizations.47 
The WHO promotes education as an 
appropriate way to “improve awareness and 
understanding of genetics in general, and 
the medical potential of genomics in 
particular”.48   
 
The World Medical Association, an 
international organization of physicians, 
recognizes the important educator role of 
physicians.49 Additionally CIOMS, and 
several international professional 
associations, recognize the influential voice 
of professionals in helping the public 
understand genetics and population 
health.50 Other than recognizing the 
important role of general practitioners,51 
geneticists are reminded that “…they have 
much to learn from support and advocacy 
groups representing those with genetic 
disorders”;52 that nurses and genetic 
counselors should educate “the public 
regarding the expanding role of genetics and 
genomics as integral components in the 
promotion of the public’s health and well-
being”;53 that researchers are considered 
educators,54 and that public and private 
research institutes should support public 
education programs that communicate 
“correct and full information”.55 Finally, 
according to the Council of Europe, the 
media plays an important role in the 
dissemination of information about genetics, 
and are considered key players in promoting 
“the widest possible participation by citizens 
in the discussion on the human genome”.56  
 
ii) Direct  and indirect involvement 
 
Direct or indirect involvement includes 
organizations, networks and stakeholder 
groups from patient groups, citizens, and 
communities. The nature of the involvement 
will be considered indirect or direct. Indirect 
involvement is one-way communication, 
such as using a consultation or a survey. 
Direct involvement is a two-way 
communication process and includes citizen 
workshops, dialogue, and deliberative and 
consensus conferences. A range of direct 
and indirect participation tools is outlined in 
the OECD handbook.57  
 
Our review of policy statements indicates 
that both consulting the public (indirect/one-
way) and involving the public in the decision-
making process (direct/two-way) are 
noteworthy for the development of public 
health policies.  
 
The WHO has a longstanding interest in 
public involvement and recommends active 
participation by those interested and 
affected; building partnerships in decision 
making,58 bringing together various cultural 
and religious perspectives about genetics 
and inheritance,59 closer cooperation with 
patient and parent organizations,60 public 
debates on the establishment of new genetic 
databases,61 seeking the “voice” of the 
developing world, and developing networks 
of collaborating centres.62 Furthermore, the 
WHO expects the World Health Assembly to 
“convene a public, high level meeting with  
the Director General”,63 to ensure the 
organization is appropriately informed.   
 
As early as 1996, HUGO supported a 
participatory model and called for full 
collaboration between researchers and the 
community.64 The policy statement 
Principled Conduct of Genetics Research 
encourages collaboration, co-operation, and 
co-ordination between individuals, 
populations, industrialized, and developing 
countries to promote scientific progress and 
as a source of “present or future benefit of 
all participants”.65 To further public 
participation in research, the suggestion is 
that “…where possible, representatives of 
participants in this research” should be 
involved in the review process.66    
 
At the regional level, the Council of Europe 
creates an obligation for indirect involvement 
by requiring parties to “see to it that the 
fundamental questions raised by the 
developments of biology and medicine are 
the subject of appropriate public discussion 
[…] and that their possible application is 
made the subject of appropriate 
consultation”.67  
 
As example of direct involvement from an 
interest group, Disabled Peoples’ 
International (DPI), recommends “…the 
involvement of persons with disabilities at all 
levels in advice, information, education, and 
decision making concerning bioethics must 
be ensured”.68 
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Who is and who represents the public? 
 
The question of who is the public is an 
important one. There are many different 
“publics”; for example ordinary citizens, 
research participants, patients, individuals 
living in specific  neighborhoods, and 
stakeholder groups representing individuals 
who may be interested in or affected by 
public policy. We distinguish two main 
categories: i) the general public (eg lay 
public, citizens), and ii) stakeholders 
representing voices from patient 
organizations involved in the policy-making 
process.  
 
i) Several policy statements focus on the 
general public. For example, the WHO 
states that “genetic education should target 
the general public”.69 UNESCO’s  Universal 
Declaration on the Human Genome and 
Human Rights, and International Declaration 
on Human Genetic Data adopt a broad and 
diffused approach and point to the need to 
reach society at large.70 The International 
Society of Bioethics notes that the public 
should comprise a broad representation of 
“…citizens from different backgrounds”.71 
 
ii) More frequently,  the role of stakeholders 
is mentioned in policy statements 
addressing public health genomics.72 The 
heterogeneity of stakeholder groups is vast 
and includes vulnerable groups,73 support 
and advocacy groups,74 persons and, more 
specifically, women with disabilities,75 
umbrella organizations,76 parents,77 patients 
and families, consumer groups, public 
watchdogs,78 civil societies, and 
communities characterized by family, 
geography, ethnicity, or religion.79 Such 
diversity of stakeholders makes it difficult to 
assess who represents the public in the 
context of public health genomics.     
 
What are the outcomes of public 
involvement?   
 
A key feature of public involvement must be 
the consideration of outcomes--in other 
words, is public involvement doing any 
good?  While this question is increasingly 
raised, outcome studies are relatively rare.80 
The problem is that to get meaningful 
evaluations there must be clear and 
consistent terminology to describe public 
involvement, to define effectiveness, to 
develop evaluation designs, and to promote 
reliable measurement tools.81  
 
The importance of outcome evaluation has 
been addressed in several policy 
statements. The WHO considers “the need 
to summarize tested and proven methods of 
public engagement and explore other 
innovative ways of promoting public 
dialogue”.82 The European Group on Ethics 
in Science and Technologies mentions that 
“studies at the community level on the 
interaction between research and 
development on the one hand, and of 
society on the other (dialogue between the 
scientific community, public perception of 
research and new technologies, role of the 
media...) should be strengthened”.83 HUGO 
mentions rightly that “without continuing 
evaluation, the potential for exploitation, 
duplicity, or abandonment, and abuse by all 
cannot be ignored. Like competence, 
continual review is imperative to respecting 
human dignity in international collaborative 
genetic research”.84 
 
Discussion 
 
Historically, public health policies 
addressing, for example, newborn 
screening, predictive genetic testing, 
pharmacogenetics and  genomic research 
using biobanks have been  created by 
researchers and health professionals, with 
patients and research participants either left 
out of the policy development process, or if 
they were consulted, it appeared as lip 
service to the principle of public 
involvement.85  Increasingly, governments 
and health professionals recognize the need 
to strengthen public involvement, and to 
inform, consult and actively engage the 
public in policy-making. It is reassuring that 
there is emphasis at the international level 
on public contribution to the development of 
policies in public health genomics. To help 
untangle the complex issues that underlie 
public involvement we have addressed four 
specific questions and noted the following:  
 
First, two predominant values emerge in the 
document review: public engagement is 
considered important to build trust and to 
show openness or transparency. It is 
important to note some reference to the fact 
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that public involvement is a prerequisite to 
public responsibility insofar as it furthers 
both equity and democracy, especially in the 
context of culturally sensitive issues.   
 
Second, we distinguish and categorize 
public participation as two distinct 
processes: education and participation. We 
note that most policy statements focus 
primarily on the need for education. 
Professional organizations tend to place the 
emphasis on education whereas non-
governmental organizations like the World 
Health Organization, UNESCO, the 
European Commission and HUGO tend to 
promote two-way interactions between 
professionals and the public.  
 
Third, definitions of “the public” focus on 
stakeholders and patient groups, however 
the general public is also mentioned as an 
important actor. Although both stakeholder 
groups and the general population are 
mentioned, they differ in their motivation. 
Patient groups generally focus on illness 
experiences, whereas the general 
population brings more general concerns to 
the discussion. It will be important to ask 
who represents patient groups and who 
represents the general population. In a 
multicultural society this is not an easy task. 
Recruiting for public participation should 
take into account social diversity including 
varying levels of education, socio-economic 
status, political affiliation, demographic 
characteristics such as age, race and 
ethnicity, disability, gender and sex, and 
religion. These characteristics and others 
may influence values, knowledge of the 
issues, and the applicability of the findings. 
A broad representation of the population or 
of stakeholder groups has the potential to 
produce results that will be widely accepted, 
as well as enhance respect between diverse 
groups with varying opinions, and respond 
to varying needs and concerns.  
 
Fourth, evaluating the impact of public 
involvement is complex and underdeveloped.  
A major reason is that in general there is no 
well defined evaluation process, and thus 
the effectiveness of public involvement is not 
well known.  Research in this area will be 
highly relevant. 
 
 
Conclusion 
 
To conclude, these are the early days of 
public health genomics. There is growing 
awareness that the door must be open for 
patients, patient organizations and the public 
to participate and explore the ethical, legal 
and social implications of these new 
developments. However, the challenges 
facing the implementation of public 
involvement are many. This review suggests 
that the complexity of public involvement, 
such as: what are the assumptions? who is 
the public? how, and, to what end? must be 
addressed. Moreover, an important question 
remains as to whether the outcome of public 
involvement is in fact made use of by policy 
makers. 
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